Roche

SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:
Roche extends tender offer for Spark Therapeutics, again
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Roche
Spark Therapeutics
M&A
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
Fierce Biotech
Roche
ASH2019
non-Hodgkin lymphoma
mosunetuzumab
Flag link:
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
Fierce Pharma
AbbVie
Roche
CLL
ASH2019
Venclexta
Flag link:
FDA approves Roche’s MRSA test, allowing for faster screening
FDA approves Roche’s MRSA test, allowing for faster screening
Pharmaforum
FDA
Roche
MRSA
diagnostics
cobas vivoDx
Flag link:
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Pharmaforum
Novartis
Roche
SMA
risdiplam
branaplam
Flag link:
Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC
Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC
Pharmaceutical Business Review
Roche
Tecentriq
metastatic non-squamous non-small cell lung cancer
FDA
Flag link:
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Fierce Pharma
Roche
Mylan
Herceptin
biosimilar
cancer
oncology
Ogivri
Flag link:
Roche trumpets data for Soliris rival in NMOSD after US, EU filings
Roche trumpets data for Soliris rival in NMOSD after US, EU filings
Pharmaforum
Roche
satralizumab
neuromyelitis optica spectrum disorder
NMOSD
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
Drugs firms make massive discounts to get reimbursement in China
Drugs firms make massive discounts to get reimbursement in China
Pharmaforum
Roche
Novartis
China
reimbursement
Flag link:
Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says
Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says
Fierce Pharma
Roche
Genentech
Xofluza
pediatrics
Flag link:
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Endpoints
Roche
Xofluza
Japan
Shionogi
Flu
influenza
Flag link:
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Endpoints
Roche
PTC Therapeutics
SMA
risdiplam
Biogen
Spinraza
Flag link:
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Flag link:
Which asthma biologic do docs prefer? It's not that simple: analyst
Which asthma biologic do docs prefer? It's not that simple: analyst
Fierce Pharma
asthma
Roche
Novartis
Xolair
Sanofi
Regeneron
Dupixent
physicians
Flag link:
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Endpoints
Roche
M&A
Spark Therapeutics
Flag link:
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
Flag link:
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Reuters
Roche
Promedior
idiopathic pulmonary fibrosis
M&A
Flag link:

Pages